Stem Cell Therapy

for Osteoarthritis & Disc Disease

About Cell Technologies

Osteoarthritis (OA) and Degenerative Disk Disease are two common chronic diseases affecting millions of people globally with devastating medical and economic impacts. Cell Tech is a clinical stage biotech company advancing the first ever FDA and Health Canada-approved stem cell technology to market. Cell Tech’s unique position is based on our proprietary technology with a solid moat of 6 patents and multiple publications. Stem Cells are the cornerstone of contemporary regenerative medicine applications. 

Our autologous and allogeneic platforms can generate live, robust cGMP stem cells directly at the point of care and are engineered to regenerate damaged tissue. Our stem cells are the only ones able to specifically target and treat arthritis. Human studies validating the technology showed a breakthrough success. Cell Tech is launching late stage trial and eyeing Exclusive Market Authorization (EMA) in Canada, granting it as the exclusive stem cell provider in Canada for 100% market share for the next 8 years and is introducing the first FDA Approved Stem Cells in the US for Osteoarthritis. 

Our Mission

Arthritis, alongside Degenerative Disk Disease, presents significant challenges globally, both medically and economically. Cell Tech's mission is to alleviate these burdens with cutting-edge solutions.

Management and Directors

  • Dr. Shammaa is a pioneer scientist in the fields of cell therapy and biologics and holds several patents in the field. He conducted the first successful spinal discs repair using stem cells in Canada.

    Dr. Riam Shammaa, MD, founded several successful companies in the field biotechnology including Pallianera Pharma and Intellistem Technologies based on his own research. And he led the development of multiple successful therapeutics to the market.

    Dr. Shammaa worked in research at McGill University and in the private sector before completing his residency in family medicine at McGill University. He went on to complete a fellowship in Sports medicine at the University of Toronto. He is a published author and a world-renowned expert in cell therapy and translational medicine.

  • Sheona is experienced in providing public company and corporate secretary services, stakeholder relations, and corporate governance and human capital advisory. She currently holds the positions of Chief Executive Officer at Limelight Capital Services Inc. (September 2019 to present), Director of Corporate Relations at ARO Consulting Inc. (December 2021 to present), and Partner and Corporate Secretary at Black Spruce Industries Inc. (June 2010 to present). She previously held the position of Operations Manager and Securities Paralegal at Bacchus Law Corporation (December 2017 to September 2019). Sheona holds a Bachelor of Business Administration (BBA) from Capilano University.

  • Katina is an experienced business-oriented lawyer. She provides advisory services on corporate strategy, public markets, corporate governance best practices, transactions , intellectual property, negotiation, privacy and international markets. Katina holds a law degree from York University -Osgoode Hall Law School and is licensed to practice law in the province of Ontario. She also holds a Master of Science from the University of Toronto and is a registered patent agent in Canada and the United States. Katina is also a Chartered Director.

  • Dr. Murphy graduated from Queen’s University with a degree in Life Science in 1988, and from the Queen’s School of Medicine in 1990. From 1990-1995, he completed his Anaesthesia training at Kingston General Hospital and Queen’s University.

    Dr. Murphy completed a Fellowship in Paediatric Anaesthesiology at Harvard-affiliated Boston Children’s Hospital from 1996-1997. He was an Assistant Professor at Queen’s University from 1997 until 2002 when he left to practice anesthesiology at Samaritan Medical Center in Watertown, New York. In 2003, Dr. Murphy became the Chair of Samaritan’s Anesthesiology Department and was instrumental in establishing the hospital’s first Pain Clinic.

    Dr. Murphy returned to Kingston, in 2008, to open KOPI, where he is presently Medical Director and again associated with Queens University as an assistant professor and resident teacher in interventional chronic pain.

    Dr. Murphy has a special interest in safe opioid prescribing and regenerative medicine. He has been an executive member of the OMA chronic pain section and is passionate about the safe provision of interventional care for patients who suffer from chronic pain.

  • Launa has over two decades of leadership experience in the life sciences sector. She currently holds. the positions of Senior Scientific and Clinical Advisor at Model Medicines (April 2024 to present), Board Chair at Applied Pharmaceutical Innovation (September 2020 to present), and Board Member at Edmonton Unlimited (April 2023 to present). Launa previously held the positions of Chief Operating Officer at TRIO - Translational Research Oncology (December 2015 through May 2022). Launa obtained her PhD in Pharmaceutical Sciences (Neurochemistry) from the University of Alberta.

  • Patricia's work experience covers multinational, dual listed, large-cap and mid-cap public companies. These companies include Green For Life Environmental (GFL) where she held the position of Senior Vice President, Finance (March 2020 through July 2021), Parkland Fuel where she held the position of Vice President Finance and Corporate Services amongst others (2015 through March 2020), as well as Nexii Building Solutions where she held th position of Executive Vice President and Chief Financial Officer (July 2021 through February 2023). Patricia is currently the Chief Executive Officer of Bridge Advisory Group Inc. and a Corporate Director for Canada Powered By Women and Arts Commons. Additionally, Patricia worked at the Alberta Securities Commission (ASC) in Corporate Finance for six years.

  • Dr. Moutih Rafei, Chief Scientific Officer of Defence Therapeutics, is an immunologist by training with a special focus on translational research in immuno-oncology. With a PhD in Experimental Medicine from McGill University, Dr. Rafei is a leader in the development of immune-related therapies for catastrophic illnesses. He has accumulated profound knowledge and insight in the fields of T-cell development, stem cell biology, cancer immunotherapy, and autoimmune diseases. His research has uncovered many seminal discoveries in thymopoiesis and cancer vaccination. Dr Rafei received over 20 awards and recognitions over the last 15 years. His research has resulted in over 75 presentations, 52 high-impact peer-reviewed publications, 5 reviews, 2 book chapters, 1 monograph, and 6 patents.